[go: up one dir, main page]

TR200003432T2 - Alfa1beta1 birleştirici alıcı önleyicilerinin kullanılması ve böbrek hastalığının tedavisinde TGF-beta1 önleyicileri. - Google Patents

Alfa1beta1 birleştirici alıcı önleyicilerinin kullanılması ve böbrek hastalığının tedavisinde TGF-beta1 önleyicileri.

Info

Publication number
TR200003432T2
TR200003432T2 TR2000/03432T TR200003432T TR200003432T2 TR 200003432 T2 TR200003432 T2 TR 200003432T2 TR 2000/03432 T TR2000/03432 T TR 2000/03432T TR 200003432 T TR200003432 T TR 200003432T TR 200003432 T2 TR200003432 T2 TR 200003432T2
Authority
TR
Turkey
Prior art keywords
inhibitors
tgf
beta1
kidney disease
treatment
Prior art date
Application number
TR2000/03432T
Other languages
English (en)
Inventor
Cosgrove Dominic
Original Assignee
Boys Town National Research Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boys Town National Research Hospital filed Critical Boys Town National Research Hospital
Publication of TR200003432T2 publication Critical patent/TR200003432T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00—Materials not provided for elsewhere
    • C09K3/18—Materials not provided for elsewhere for application to surfaces to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Combustion & Propulsion (AREA)
  • Materials Engineering (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Mevcut bulus, böbrek bozukluklarinin (örn. böbrek glomerülonefrit ve/veya böbrek fibrozu) tedavi edilmesi (yani, baslangicinin geciktirilmesi, ilerlemesinin yavaslatilmasi ve/veya geri çevrilmesi için yöntemler sunar.Bu yöntemlerin bazilari, istege bagli olarak bir TGF-beta1 önleyicisi ile birlikte alfa1beta1 birlestirici alici önleyicisinin verilmesini içerir. Mevcut bulus ayrica farenin GBM'de normal bir 4 tipi kolajen kompozisyonunu ifade etmedigi ( yani kolajen alfa3(IV), alfa4(IV), alfa5(IV) kolajen zincirlerini glomerül taban zarina dahil etmedigi) ve alfa1beta1 birlestirici alicisini ifade etmedigi, böbrek hastaligi için bir fare modeli sunar.
TR2000/03432T 1998-05-22 1999-05-19 Alfa1beta1 birleştirici alıcı önleyicilerinin kullanılması ve böbrek hastalığının tedavisinde TGF-beta1 önleyicileri. TR200003432T2 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8658798P 1998-05-22 1998-05-22
US8876698A 1998-06-02 1998-06-02
US15048598A 1998-09-09 1998-09-09

Publications (1)

Publication Number Publication Date
TR200003432T2 true TR200003432T2 (tr) 2001-03-21

Family

ID=56289911

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03432T TR200003432T2 (tr) 1998-05-22 1999-05-19 Alfa1beta1 birleştirici alıcı önleyicilerinin kullanılması ve böbrek hastalığının tedavisinde TGF-beta1 önleyicileri.

Country Status (21)

Country Link
EP (1) EP1079843B1 (tr)
JP (1) JP2002516287A (tr)
CN (1) CN1187084C (tr)
AT (1) ATE359804T1 (tr)
BR (1) BR9911067A (tr)
CA (1) CA2329757C (tr)
CZ (1) CZ296262B6 (tr)
DE (1) DE69935853T2 (tr)
DK (1) DK1079843T3 (tr)
EA (1) EA004145B1 (tr)
EE (1) EE04581B1 (tr)
ES (1) ES2285841T3 (tr)
HU (1) HUP0202048A3 (tr)
NO (1) NO20005883L (tr)
NZ (1) NZ508317A (tr)
PL (1) PL345946A1 (tr)
PT (1) PT1079843E (tr)
SG (1) SG117434A1 (tr)
SI (1) SI1079843T1 (tr)
TR (1) TR200003432T2 (tr)
WO (1) WO1999061040A2 (tr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0202568A3 (en) 1999-06-01 2009-11-30 Biogen Idec Inc A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
ATE325623T1 (de) * 1999-09-14 2006-06-15 Biogen Idec Inc Therapien für chronische niereninsuffizienz unter verwendung von einem oder mehreren integrinantagonist(en)
PT1263464E (pt) * 2000-03-09 2012-12-17 Genzyme Corp Utilização de anticorpos anti-tgf-beta antagonistas para tratar ou para prevenir a perda da função renal
UA83791C2 (ru) 2001-04-13 2008-08-26 Байоджен Айдек Ма Инк. Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
US7348002B2 (en) * 2002-11-01 2008-03-25 Boys Town National Research Hospital Inducible ligand for α1β1 integrin and uses
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
EP2034830B1 (en) 2006-05-25 2014-09-03 Biogen Idec MA Inc. Anti-vla-1 antibody for treating stroke
GB0911888D0 (en) * 2009-07-08 2009-08-19 Oxford Biodynamics Ltd Method of treating age related disorders
SI2702155T1 (sl) 2011-04-25 2017-07-31 Regulas Therapeutics Inc. Spojine MicroRNA in postopki za modulacijo aktivnosti MIR-21
NZ629204A (en) 2012-02-16 2016-09-30 Santarus Inc Anti-vla1 (cd49a) antibody pharmaceutical compositions
AU2013251696B2 (en) 2012-04-25 2018-11-15 Sanofi MicroRNA compounds and methods for modulating miR-21 activity
UA116639C2 (uk) * 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
CN104450726A (zh) * 2013-09-17 2015-03-25 深圳华大基因科技有限公司 Col4a5基因突变体及其应用
CN104212806B (zh) * 2014-07-21 2017-05-17 深圳华大基因股份有限公司 Alport综合征新的突变致病基因及其编码蛋白和应用
EP4225302A1 (en) * 2020-10-05 2023-08-16 Father Flanagan's Boys' Home doing Business as Boys Town National Research Hospital Combination therapy for alport renal disease
CN112575074B (zh) * 2020-10-09 2022-12-27 中山大学 Nestin基因及蛋白在治疗器官纤维化中的应用
EP4431098A4 (en) * 2021-11-12 2025-10-08 Ube Corp PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF ALPORT SYNDROME
CN114698592B (zh) * 2022-04-29 2022-11-04 中国医学科学院北京协和医院 一种干燥综合征肾损害小鼠模型的构建方法及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9519667D0 (en) * 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition

Also Published As

Publication number Publication date
BR9911067A (pt) 2001-02-06
PL345946A1 (en) 2002-01-14
SG117434A1 (en) 2005-12-29
CN1310625A (zh) 2001-08-29
EA004145B1 (ru) 2004-02-26
SI1079843T1 (sl) 2007-10-31
NZ508317A (en) 2004-01-30
CA2329757A1 (en) 1999-12-02
EE200000685A (et) 2002-04-15
ES2285841T3 (es) 2007-11-16
CZ20004358A3 (cs) 2002-01-16
NO20005883D0 (no) 2000-11-21
EP1079843A2 (en) 2001-03-07
EP1079843B1 (en) 2007-04-18
CA2329757C (en) 2013-11-19
DE69935853T2 (de) 2008-01-10
HUP0202048A3 (en) 2006-11-28
EA200001092A1 (ru) 2001-06-25
ATE359804T1 (de) 2007-05-15
HUP0202048A2 (en) 2002-10-28
PT1079843E (pt) 2007-06-26
WO1999061040A9 (en) 2001-02-01
WO1999061040A2 (en) 1999-12-02
CZ296262B6 (cs) 2006-02-15
EE04581B1 (et) 2006-02-15
NO20005883L (no) 2001-01-17
DK1079843T3 (da) 2007-07-30
WO1999061040A3 (en) 2000-01-27
JP2002516287A (ja) 2002-06-04
CN1187084C (zh) 2005-02-02
DE69935853D1 (de) 2007-05-31

Similar Documents

Publication Publication Date Title
TR200003432T2 (tr) Alfa1beta1 birleştirici alıcı önleyicilerinin kullanılması ve böbrek hastalığının tedavisinde TGF-beta1 önleyicileri.
TR200000756T2 (tr) Davranış bozukluğu tedavisi.
IL143901A0 (en) Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
TR200100605T2 (tr) Arilpiperazinler ve bunların metaloproteinaz inhibe edici maddeler (MMP) olarak kullanımı
DE69900603D1 (de) Katalitische zusammenstellung
TR199801348T2 (tr) Heterosikl-kondanse morfinoid türevleri(II).
TR199801255T2 (tr) Vitronektin reseptör antagonistleri.
DE60106954D1 (de) Resorcin-derivate
AR045528A2 (es) Sales de ziprasidona
DE50214926D1 (de) Wertdokument
DE69822162D1 (de) Neue tetrazolderivate
BR9806752A (pt) Ftalazinonas.
NO992282D0 (no) Benzonaftyridiner som bronkialterapentika
TR199800644T2 (tr) Bir apoptoz inhibitörü olarak y-RAR antagonist ligandi ya da alfa-RAR antagonist ligandi.
DE69913020D1 (de) Transparente Antischuppen-Haarwaschzusammensetzungen
TR199801452T2 (tr) Jinekolojik rahatsizliklarin tedavisinde kullanilan LHRH analoglari ve antiöstrojenlerden mütesekkil farmakolojik kombine madde.
BR0012675A (pt) Uso de inibidores de il-18
BR9804749A (pt) Tratamento de purido.
BR9801143A (pt) Copolìmeros de bloco de siloxano inovativos com espaçamento rìgidos e uso dos mesmos.
TR200002939T2 (tr) Paroksetin maleat
DK0841937T3 (da) Anvendelse af betaglycan til reduktion af ardannelse
TR199901307T2 (tr) Oral skuamöz hücre karsinomu için lökotrien antagonistleri
DK1144423T3 (da) Bis-terpyridin-platin(II)-komplekser
TR200200207T2 (tr) C. Albicans esas genleri ve antimikotik maddelerin taranması yöntemi
RU2000131467A (ru) Эмульсионный раствор